Oral antidiabetic agents as cardiovascular drugs

Diabetes, Obesity and Metabolism

Volumn 9, Issue 1, 2007, Pages 23-30

  Macfarlane, Dave P ^a   Paterson, K R ^a   Fisher, M ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Acarbose; Cardiovascular disease; Diabetes; Meglinitide analogues; Metformin; Oral antidiabetic agents; Sulphonylureas; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; BUFORMIN; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENFORMIN; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; TOLBUTAMIDE; TROGLITAZONE; VALSARTAN;

ABDOMINAL DISCOMFORT; ADD ON THERAPY; ANEMIA; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; FLATULENCE; FLUID RETENTION; GASTROINTESTINAL TOXICITY; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIVER TOXICITY; LONG TERM CARE; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

EID: 33845542023     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00592.x     Document Type: Review

References (75)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979; 241: 2035-2038.
2. Schernthaner G. Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diabetes Res Clin Pract 1996; 31: S3-S13.
3. Fisher M. Diabetes: Can we stop the time bomb? Heart 2003; 89 (Suppl. 2): 28-30.
4. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Organization, Department of Noncommunicable Disease Surveillance, 1999.
5. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and non cardiovascular diseases? Diabetes Care 2003; 26: 688-696.
6. Saydah SH, Loria CM, Eberhardt MS et al. Subclinical state of glucose intolerance and risk of death in the U.S. Diabetes Care 2001; 24: 447-453.
7. Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirements for multiple therapies. JAMA 1999; 281: 2005-2012.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
9. Stumvoll M, Goldstein BJ, Van Haeften TW. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346.
10. Bailey CJ, Day C. Antidiabetic drugs. Br J Cardiol 2003; 10: 128-136.
11. Kennedy DL, Piper JM, Baum C. Trends in the use of oral hypoglycemic agents, 1964-1986. Diabetes Care 1988; 11: 558-562.
12. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol 1989; 54: 87-143.
13. Matthews DR, Cull CA, Stratton IM et al. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 1998; 15: 297-303.
14. Gerich JE. Oral hypoglycaemic agents. N Engl J Med 1989; 321: 1231-1245.
15. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004; 64: 1339-1358.
16. Stratton IM, Adler AI, Neil AW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 32: 405-412.
17. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, III: clinical implications of UGDP results. JAMA 1971; 218: 1400-1410.
18. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
19. Abdella NA. Controversies in management of diabetes in patients with coronary heart disease. Med Princ Pract 2002; 11 (Suppl. 2): 69-74.
20. Gross G, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992; 70: 223-233.
21. Toombs CF, Moore TL, Shebuski RJ. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardivasc Res 1993; 27: 617-622.
22. Nichols CG, Ripoll C, Lederer WJ. ATP-sensitive potassium channel modulation of the guinea pig ventricular action potential and contraction. Circ Res 1991; 68: 280-287.
23. Langtry HD, Balfour JA. Glimepiride: A review of its use in the management of type 2 diabetes mellitus. Drugs 1998; 55: 563-584.
24. Fuhlendorff J, Rorsman P, Kofod H et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-351.
25. Bokvist K, Høy M, Buschard K et al. Selectivity of prandial glucose regulators: Nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic A-cells. Eur J Pharmacol 1999; 386: 105-111.
26. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001; 358: 1709-1716.
27. Kristensen JS, Frandsen KB, Bayer T et al. Repaglinide treatment is associated with significantly less severe hypoglycaemic events compared to sulphonylurea. Diabetologia 1999; 42 (Suppl. 1): A4.
28. Hedberg TG, Huang W-C. Repaglinide: A double-blind, randomized, dose-response study. Diabetologia 1998; 41 (Suppl. 1): A235.
29. Rosenstock J, Hassman DR, Madder RD et al. Repaglinide versus nateglinide monotherapy: A randomized, multicenter study. Diabetes Care 2004 27: 1265-1270.
30. The NAVIGATOR Trial Steering Committee. Nateglinide and valsartan in impaired glucose tolerance outcomes research, rationale and design of the NAVIGATOR trial. Diabetes 2002; 51 (Suppl. 2): A116.
31. Witters LA. The blooming of the French lilac. J Clin Invest 2001; 108: 1105-1107.
32. Nattrass M, Alberti KGMM. Biguanides. Diabetologia 1978; 14: 71-74.
33. Jackson RA, Hawa MI, Jaspan JB et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 1987; 36: 632-640.
34. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
35. Despres JP, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
36. Ruige JB, Assendelft WJ, Dekker JM et al. Insulin and risk of cardiovascular disease: A meta-analysis. Circulation 1998; 97: 996-1001.
37. Hermann LS, Scherstén B, Bitzén PO et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17: 1100-1109.
38. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. BMJ 2003; 326: 4-5.
39. Grant PJ, Stickland MH, Booth NA et al. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med 1991; 8: 361-365.
40. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993; 16: 621-629.
41. Charles MA, Morange P, Eschwège E et al. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: The BIGPRO1 Study. Biguanides and the Prevention of the Risk Obesity. Diabetes Care 1998; 21: 1967-1972.
42. Buse JB, Tan MH, Prince MJ et al. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004; 6: 133-156.
43. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 1344-1350.
44. Jadhav ST, Sattar N, Ferrell WR et al. Effects of metformin on microvascular dysfunction, metabolic parameters and ischaemic measures in women with cardiac syndrome X: A double-blind randomised placebo-controlled trial. Circulation 2003; 108: 562-563.
45. Murphy EJ, Davern TJ, Shakil AO et al. Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig Dis Sci 2000; 45: 549-553.
46. Lebovitz HE. Differentiating members of the thiazolidinedione class: A focus on safety. Diabetes Metab Res Rev 2002; 18 (Suppl. 2): S23-S29.
47. Day C. Thiazolidinediones: A new class of antidiabetic drugs. Diabet Med 1999; 16: 179-192.
48. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 1999; 48: 2414-2421.
49. Higgs ER, Krentz AJ. ABCD position statement on glitazones. Pract Diabetes Int 2004; 21: 293-295.
50. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164: 2097-2104.
51. Derosa G, Cicero AFG, Gaddi A et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744-754.
52. Scherbaum W, Burkhard G. The German pioglitazone Study Group. Pioglitazone reduces blood pressure in patients with type 2 diabetes. Diabetes 2001; 50 (Suppl. 2): A462.
53. Bakris GL, Dole JF, Porter LE, Huang C, Freed M. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus. Diabetes 2000; 49 (Suppl. 1): A96.
54. Bennet SMA, Jones NP, Agrawal A et al. Rosiglitazone improves insulin sensitivity and 24-h ambulatory blood pressure in subjects with impaired glucose tolerance. Diabetologia 2001; 44 (Suppl. 1): A770.
55. Sjoholm A, Nystrom T. Endothelial inflammation in insulin resistance. Lancet 2005; 365: 610-612.
56. Theuma P, Fonseca VA. Inflammation, insulin resistance, and atherosclerosis. Metab Syndr Relat Disord 2004; 2: 105-113.
57. Watanabe Y, Sunayama S, Shimada K et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb 2000; 7: 159-163.
58. Imano E, Kanda T, Nakatani Y et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21: 2135-2139.
59. Koshiyama H, Shimono D, Kuwamura N et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456.
60. Choi D, Kim S-K, Choi S-H et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654-2660.
61. Nesto R. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 2004; 21: 810-817.
62. Murakami T, Mizuno S. Effects of thiazolodinedione on effort induced angina pectoris with type-2 diabetes mellitus. Circulation 2000; 102 (Suppl. 2): 706-707.
63. Murakami T, Mizuno S, Ohsato K et al. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol 1999; 84: 92-94.
64. Kelly IE, Han TS, Walsh K et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-293.
65. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
66. Viberti G, Kahn SE, Douglas A et al. A diabetes outcome progression trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25: 1737-1743.
67. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD): Study design and protocol. Diabetologia 2005; 48: 1726-1735.
68. Balfour JA, McTavish D. Acarbose: An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46: 1025-1054.
69. Lebovitz HE. alpha-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998; 6: 132-145.
70. Chiasson JL, Josse RG, Gomis R et al. STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077.
71. Chiasson JL, Josse RG, Gomis R et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003; 290: 486-494.
72. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16.
73. Kaiser T, Sawicki PT. Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data. Diabetologia 2004; 47: 575-580.
74. Van De Laar FA, Lucassen PLBJ. No evidence for a reduction of myocardial infarctions by acarbose. Eur Heart J 2004; 25: 1179.
75. Van De Laar FA, Lucassen PL, Akkermans RP, Van De Lisdonk EH, Rutten GE, Van Weel C. a-Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163.